Federal contract award
75F40124C00080
FDABAA-24-00123: DEVELOPMENT OF MODERNIZED SUSCEPTIBILITY GUIDANCE FOR NITROFURANTOIN DOSING USING A DYNAMIC URINARY TRACT IN VITRO INFECTION MODEL AND PHARMACOMETRIC APPROACHES - FY24C3BP4
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | FDA OFFICE OF ACQ GRANT SVCS |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | B529 — Scientific Data Studies |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $248.6K |
| Current contract value | $248.6K |
| Potential contract value / ceiling | $248.6K |
| Start date | Aug 19, 2024 |
| Current end date | Oct 29, 2025 |
| Potential end date | Oct 29, 2025 |
| Latest award activity | Aug 25, 2025 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 3 of 3 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Aug 25, 2025 | P00002 | $0 | FDABAA-24-00123: DEVELOPMENT OF MODERNIZED SUSCEPTIBILITY GUIDANCE FOR NITROFURANTOIN DOSING USING A DYNAMIC URINARY TRACT IN VITRO INFECTION MODEL AND PHARMACOMETRIC APPROACHES - FY24C3BP4 |
| Mar 11, 2025 | P00001 | $0 | FDABAA-24-00123: DEVELOPMENT OF MODERNIZED SUSCEPTIBILITY GUIDANCE FOR NITROFURANTOIN DOSING USING A DYNAMIC URINARY TRACT IN VITRO INFECTION MODEL AND PHARMACOMETRIC APPROACHES - FY24C3BP4 |
| Aug 19, 2024 | 0 | $248.6K | FDABAA-24-00123: DEVELOPMENT OF MODERNIZED SUSCEPTIBILITY GUIDANCE FOR NITROFURANTOIN DOSING USING A DYNAMIC URINARY TRACT IN VITRO INFECTION MODEL AND PHARMACOMETRIC APPROACHES - FY24C3BP4 |
Buyer contacts from matching notices
Matched on exact award/solicitation identifier and awarding agency. Source dates describe the notice, not current contact verification.
| Contact | Role | Published contact methods | Evidence | Source date |
|---|---|---|---|---|
| Ian Weiss | Contact | Ian.Weiss@fda.hhs.gov 3017965728 | Source | Jan 25, 2024 |
| Ian Weiss | Contact | Ian.Weiss@fda.hhs.gov 3017965728 | Source | Jan 16, 2024 |
| Ian Weiss | Contact | Ian.Weiss@fda.hhs.gov 3017965728 | Source | Dec 28, 2023 |
| Ian Weiss | Contact | Ian.Weiss@fda.hhs.gov 3017965728 | Source | Nov 2, 2023 |
| Ian Weiss | Contact | Ian.Weiss@fda.hhs.gov 3017965728 | Source | Oct 20, 2023 |
| Ian Weiss | Contact | Ian.Weiss@fda.hhs.gov 3017965728 | Source | Oct 18, 2023 |
| Ian Weiss | Contact | Ian.Weiss@fda.hhs.gov 3017965728 | Source | Oct 2, 2023 |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.